The stock of Roka Bioscience Inc (NASDAQ:ROKA) is a huge mover today! About 294,080 shares traded hands or 167.64% up from the average. Roka Bioscience Inc (NASDAQ:ROKA) has declined 36.11% since April 26, 2016 and is downtrending. It has underperformed by 41.37% the S&P500.
The move comes after 5 months positive chart setup for the $9.12 million company. It was reported on Nov, 29 by Barchart.com. We have $5.61 PT which if reached, will make NASDAQ:ROKA worth $547,200 more.
Analysts await Roka Bioscience Inc (NASDAQ:ROKA) to report earnings on March, 3.
Roka Bioscience Inc (NASDAQ:ROKA) Ratings Coverage
Out of 3 analysts covering Roka Bioscience (NASDAQ:ROKA), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Roka Bioscience has been the topic of 7 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The stock of Roka Bioscience Inc (NASDAQ:ROKA) earned “Hold” rating by Zacks on Tuesday, September 8. The company was downgraded on Monday, March 7 by Leerink Swann. On Friday, August 14 the stock rating was maintained by Leerink Swann with “Outperform”. The stock of Roka Bioscience Inc (NASDAQ:ROKA) earned “Hold” rating by Zacks on Tuesday, August 25.
According to Zacks Investment Research, “Roka Bioscience, Inc. is a molecular diagnostics company. It is focused on developing and commercializing advanced testing solutions for the food safety testing market. Roka provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. Roka Bioscience, Inc. is headquartered in Warren, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.50, from 0.5 in 2016Q1. The ratio improved, as 4 funds sold all Roka Bioscience Inc shares owned while 2 reduced positions. 1 funds bought stakes while 2 increased positions. They now own 11.75 million shares or 4.44% less from 12.30 million shares in 2016Q1.
Tudor Et Al accumulated 0% or 32,545 shares. Orbimed Ltd Co has 0.02% invested in the company for 3.22 million shares. Geode Ltd has invested 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA). Cannell Peter B & owns 58,098 shares or 0% of their US portfolio. Craig A accumulated 1.8% or 1.60 million shares. Bancshares Of America De reported 4,018 shares or 0% of all its holdings. Wells Fargo & Mn has 0% invested in the company for 100 shares. Renaissance Technology Limited Liability Corporation has invested 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA). Goldman Sachs Gru has 10,577 shares for 0% of their US portfolio. Blackrock Inc has invested 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA). Bridgeway Cap Mngmt holds 207,500 shares or 0% of its portfolio. Manufacturers Life Ins The last reported 0% of its portfolio in the stock. Tpg Hldgs (Sbs) reported 2.99 million shares or 0.02% of all its holdings. Weiss Multi accumulated 0% or 54,675 shares. Moreover, Vanguard Group Inc Inc has 0% invested in Roka Bioscience Inc (NASDAQ:ROKA) for 22,486 shares.
More notable recent Roka Bioscience Inc (NASDAQ:ROKA) news were published by: Prnewswire.com which released: “Roka Bioscience, Inc. Announces One-For-Ten Reverse Stock Split” on October 11, 2016, also Marketwatch.com with their article: “Roka Bioscience upgraded to outperform from market perform at Leerink Partners” published on July 17, 2014, Prnewswire.com published: “Roka Bioscience Reports Third Quarter 2016 Financial Results” on November 07, 2016. More interesting news about Roka Bioscience Inc (NASDAQ:ROKA) were released by: Prnewswire.com and their article: “Roka Bioscience, Inc. Prices Private Placement of Preferred Stock and Warrants” published on September 16, 2016 as well as Prnewswire.com‘s news article titled: “Roka Bioscience to Co-Present Industry Webinar – Play FDA for a day” with publication date: September 07, 2016.
ROKA Company Profile
Roka Bioscience, Inc., incorporated on September 3, 2009, is a molecular diagnostics company. The Firm is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Firm offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture assays, immunochemical assays and molecular assays. The Firm sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing instrument designed to reduce labor costs and operator error in foodborne pathogen testing laboratories. The Atlas instrument is a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.